Amarin Corporation

NAQ:AMRN · US0231114044

BiotechnologySmall

360

Medium confidence — indicative

Value70

Profit price—

Cash yield50

Owner Earnings Yield98

Dividend Yield1

Sales & asset price81

Price/Sales77

EV / Gross Profit100

Price/Book67

Quality60

Returns on capital85

Return on Capital83

Return on Equity87

Profit margins65

EBIT Margin67

Gross Profitability63

Cash truth not applicable for financial companies.

Growth40

Sales growth18

Profit growth67

Reinvestment17

Price momentum49

Safety—

Debt load82

Debt serviceability100

Liquidity6

Sentiment33

Analyst ratings1

Expectations trend27

Opinion Changes50

Price Target Upside4

Market mood1

Value Creation7/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Amarin Corporation clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIreland

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Founded1989

Employees227

Websiteamarincorp.com

ISINUS0231114044

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

CardiovascularDiabetesNutraceuticalBiopharmaBiotechnologyPharmaceutical

Description

Amarin Corporation plc is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. The company’s commercialized product, VASCEPA (icosapent ethyl), was fir…

Analysis

Bargain bin

Amarin Corporation plc is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

Valuation data is not available for this company.

Growth is tepid; the safety picture is uncertain. The company scores 7/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Amarin Corporation with its peers

NewAmsterdam Pharma Company

NMQ:NAMS

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Applied Nutrition

LSE:APN

CountryUK

IndustryPersonal Products

SizeSmall

Full Stock Analysis →

Alkermes

NSQ:ALKS

CountryIreland

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Anbio Biotechnology

NMQ:NNNN

—

CountryGermany

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

DocMorris

SWX:DOCM

CountrySwitzerland

IndustryFood & Staples Retailing

SizeSmall

Full Stock Analysis →

Kuros Biosciences

SWX:KURN

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →